ALT
Altimmune, Inc.
$2.20
-0.16
(-6.78%)
Mkt Cap
427.94M
Volume
4,243,455
52W Range
2.17-6.44
Sector
Healthcare
Beta
0.18
EPS (TTM)
-0.78 USD
P/E Ratio
-3.61
Revenue (TTM)
31,000 USD
Rev Growth (5Y)
-65.3%
EPS Growth (5Y)
N/A
Company Description
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 41,000 | 20,000 | 426,000 | (68,000) | 4.41M | 8.19M | 5.80M | 10.33M | 41,503 | 5.23M | 10.64M | 10.19M |
| Net Income | (88.09M) | (95.06M) | (88.45M) | (84.71M) | (97.09M) | (49.04M) | (20.52M) | (39.17M) | (46.43M) | 193.85M | (3.44M) | (9.96M) |
| EPS | -1.00 | -1.34 | -1.66 | -1.81 | -2.35 | -1.91 | -1.56 | -13.98 | -108.77 | -49.80 | -16.13 | -51.91 |
| Free Cash Flow | (67.55M) | (79.85M) | (75.86M) | (62.71M) | (90.55M) | (34.65M) | (9.60M) | (10.40M) | (20.38M) | 201.48M | (3.30M) | (8.57M) |
| FCF / Share | -0.77 | -1.12 | -1.42 | -1.34 | -2.19 | -1.35 | -0.73 | -3.71 | -47.75 | 874.54 | -15.48 | -44.67 |
| Operating CF | (67.53M) | (79.85M) | (75.81M) | (62.59M) | (78.24M) | (34.31M) | (9.60M) | (9.39M) | (20.21M) | 201.51M | (3.22M) | (8.47M) |
| Total Assets | 279.93M | 139.31M | 210.64M | 206.93M | 218.87M | 245.12M | 54.06M | 54.75M | 63.03M | 224.74M | 19.86M | 21.98M |
| Total Debt | 35.69M | 1.68M | 671,000 | 1.12M | 1.53M | 1.82M | 1.74M | 572,770 | 49,702 | 984,580 | 1.08M | 746,146 |
| Cash & Equiv | 43.76M | 36.93M | 135.12M | 111.10M | 190.30M | 115.92M | 8.96M | 33.72M | 8.77M | 153.99M | 15.57M | 18.64M |
| Book Value | 224.89M | 123.51M | 194.10M | 185.29M | 199.13M | 225.88M | 45.52M | 48.31M | 48.68M | 19.46M | 16.65M | 18.27M |
| Return on Equity | -0.39 | -0.77 | -0.46 | -0.46 | -0.49 | -0.22 | -0.45 | -0.81 | -0.95 | 9.96 | -0.21 | -0.54 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 26,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 37,000 | 362,000 |
| Net Income | (22.82M) | (22.56M) | (27.36M) | (19.01M) | (22.15M) | (19.57M) | (23.18M) | (22.84M) | (24.64M) | (24.39M) | (31.64M) | (20.67M) |
| EPS | -0.12 | -0.18 | -0.27 | -0.21 | -0.27 | -0.26 | -0.33 | -0.32 | -0.35 | -0.34 | -0.54 | -0.39 |
| Free Cash Flow | (24.25M) | (20.96M) | (19.45M) | (11.90M) | (19.36M) | (16.84M) | (18.27M) | (27.12M) | (18.11M) | (16.36M) | (16.53M) | (20.49M) |
| FCF / Share | -0.13 | -0.17 | -0.19 | -0.13 | -0.24 | -0.22 | -0.26 | -0.38 | -0.26 | -0.23 | -0.28 | -0.38 |
| Operating CF | (24.22M) | (20.94M) | (19.45M) | (11.90M) | (19.35M) | (16.84M) | (18.27M) | (27.12M) | (18.11M) | (16.36M) | (16.53M) | (20.49M) |
| Total Assets | 527.21M | 335.63M | 279.93M | 218.45M | 190.35M | 157.26M | 139.31M | 147.86M | 173.35M | 188.36M | 210.64M | 166.57M |
| Total Debt | 35.75M | 35.85M | 35.69M | 15.90M | 15.85M | 1.59M | 1.68M | 1.77M | 1.86M | 552,000 | 671,000 | 788,000 |
| Cash & Equiv | 63.05M | 97.60M | 43.76M | 61.24M | 183.10M | 49.10M | 36.93M | 31.47M | 57.13M | 78.98M | 135.12M | 86.86M |
| Book Value | 474.21M | 283.99M | 224.89M | 185.60M | 161.37M | 142.16M | 123.51M | 133.38M | 152.53M | 172.94M | 194.10M | 150.40M |
| Return on Equity | -0.05 | -0.08 | -0.12 | -0.10 | -0.14 | -0.14 | -0.19 | -0.17 | -0.16 | -0.14 | -0.16 | -0.14 |
ALT News
SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
Altair Semiconductor Integrates Iridium NTN Direct into ALT1350 and ALT1550 Cellular IoT Chipsets
Altimmune Details Pemvidutide's Path Toward a Liver-Disease Franchise
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress
Altimmune to Participate in Stifel Cardiometabolic Forum
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law
Critical Survey: Denali Therapeutics (NASDAQ:DNLI) vs. Altimmune (NASDAQ:ALT)
Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?